Q1 2026 · 13F-HR
GENERAL ATLANTIC, L.P.holdings as filed
Filed 2026-05-15 · accession 0000950142-26-001406
$2.15B
Reported value
12
Positions
2026-03-31
Period end
The Brief · GENERAL ATLANTIC, L.P. · Q1 2026
AI · grounded in 13F
GENERAL ATLANTIC, L.P. closed its entire position in Alignment Healthcare ALHC, reducing its exposure by $260,062,727. The fund also trimmed its holdings in Centessa Pharmaceuticals CNTA and Revolution Medicines RVMD, reducing share counts by 77.85% and 74.84% respectively. Conversely, the fund increased its stake in Alkami ALKT by 27.90%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G29018101 | DLO | DLOCAL | $605.1M | 28.2% | 46,656,695 | Common | SOLE |
| 16935C109 | CHYM | CHIME | $398.2M | 18.5% | 21,259,683 | Common | SOLE |
| G98239109 | XP | XP, INC | $391.6M | 18.2% | 20,566,133 | Common | SOLE |
| 01644J108 | ALKT | ALKAMI | $240.3M | 11.2% | 15,337,495 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS | $226.9M | 10.6% | 8,031,252 | Common | SOLE |
| 29882P106 | EWCZ | EUROPEAN WAX CENTER | $75.8M | 3.53% | 13,110,492 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES | $68.8M | 3.20% | 707,791 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS | $63.6M | 2.96% | 4,101,865 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS | $53.8M | 2.50% | 1,354,830 | Common | SOLE |
| M8216R109 | RSKD | RISKIFIED | $20.9M | 0.97% | 5,324,998 | Common | SOLE |
| 39957D201 | GROV | GROVE COLLABORATIVE | $3.2M | 0.15% | 2,474,859 | Common | SOLE |
| G9572D103 | BULL | WEBULL | $243,917 | 0.01% | 50,816 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.